Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part D Formulary Coverage & PA …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy HPMS Approved Formulary File Submission ID 26425

    Medicare Advantage Part D Formulary (Drug List) — Independent Health Employer Group 2026

    Customize your policy alerts

    Sign up for Independent Health Policy HPMS Approved Formulary File Submission ID 26425 alerts

    Get alerted when Policy HPMS Approved Formulary File Submission ID 26425 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is Independent Health's Medicare Advantage Employer Group Part D formulary describing covered drugs, restrictions (prior authorization, quantity limits, step therapy), member rights to exceptions, and how to find drugs in the formulary. It affects plan members, prescribers, and network pharmacies using the Independent Health Medicare Advantage Employer Group Part D benefit.

    Policy Summary
    PayerIndependent Health
    PolicyMedicare Advantage Part D Formulary (Drug List) — Independent Health Employer Group 2026
    Policy CodePolicy HPMS Approved Formulary File Submission ID 26425
    Change TypeAdministrative update — formulary file refreshedno material coverage changes noted
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting documentation when a drug line indicates 'PA' or 'PA New Starts' to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6/1/2026formulary update
    30 daysmember notice minimum
    72 hoursstandard exception decision
    24 hoursexpedited exception decision
    30-dayone-time retail transition
    34-dayLTC transition supply

    Formulary Coverage Rules & Controls

    Formulary coverage rules and member protections

    Covered when ALL of the following are met:

    Formulary coverage general: Independent Health will generally cover drugs listed on the formulary if the drug is medically necessary, the prescription is filled at an Independent Health network pharmacy, and other plan rules are followed.

    See Evidence of Coverage for details (source: Independent Health formulary description).

    Compliance with plan requirements: Prescriber and member must satisfy any Requirements/Limits listed on the formulary row (e.g., Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), EDS, LA, ENH, BD).

    Requirements/Limits flags appear in the formulary table and must be followed; failure to obtain PA may result in non-coverage.

    Transition and continuity protections: When a drug is removed or a restriction is added, affected members will be notified at least 30 days prior unless an immediate change exception applies; new or current members may receive a one-time 30-day transition supply at retail (34 days for LTC residents) while pursuing alternatives or exceptions.
    Policy Summary
    PayerIndependent Health
    PolicyMedicare Advantage Part D Formulary (Drug List) — Independent Health Employer Group 2026
    Policy CodePolicy HPMS Approved Formulary File Submission ID 26425
    Change TypeAdministrative update — formulary file refreshedno material coverage changes noted
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting documentation when a drug line indicates 'PA' or 'PA New Starts' to avoid claim denial.
    SourceLink
    On This Page
    Formulary Coverage Rules & ControlsWhat Prescribers and Pharmacies Must DoDrug Entries and Coding NotesStep Therapy & 'PA New Starts' ControlsQuantity Limits (QL) — Examples and Line ItemsSite-of-Care and Pharmacy LimitationsLegend and GlossaryBackground / Scope
    30 days / 30-day supply / 34-day LTC

    Members may request exceptions; plan provides notice and transition supplies per CMS rules.

    Exception option: Member or prescriber may request a formulary/tiering or coverage exception; plan will generally decide within 72 hours of receiving the prescriber's supporting statement (24 hours for expedited requests when clinically appropriate).72 hours / 24 hours expedited

    Exceptions may waive non-formulary status, PA, QL, or ST where medically justified.

    PA / New Starts

    Coverage and utilization management flags present for listed drugs:

    PA / PA New Starts: Products listed with 'PA' or 'PA New Starts' require prior authorization before coverage is provided; many specialty, high-tier, and oncology oral agents are marked PA New Starts.

    Examples in the formulary include WEGOVY, REPATHA formulations, and multiple oncology agents.

    Specialist exceptions for PA New Starts: Some products marked 'PA New Starts' carry specialty-based exceptions (e.g., prior authorization may not be required for neurologists for certain seizure rescue/nasal products).

    Check the formulary row for any specialist exemptions or notes.

    Operational note: Failure to obtain required prior authorization may result in the plan not covering the drug.

    Providers should follow the payer's PA process and submit required documentation.

    Quantity limits

    Quantity limited products (examples shown):

    Products with explicit QL: Some formulary lines include quantity limits expressed as maximum units per time period (e.g., sacubitril-valsartan QL 60 EA per 30 days; KERENDIA QL 30 EA per 30 days; icosapent ethyl/VASCEPA QL 120 EA per 30 days; dimethyl fumarate QL 60 EA per 30 days).see examples

    Requests exceeding listed QL may require prior authorization or be denied.

    Common QL examples: Illustrative quantity limits in the formulary include: 30 EA per 30 days, 60 EA per 30 days, 120 EA per 30 days, 600 mL per 30 days, and therapy-pack specific annual or 28-day limits (see table).varies by product

    Operate per the Requirements/Limits column for each product.

    Documentation and denial risk: Quantity limits listed (QL) may require supporting documentation when exceeded; claims may be edited or denied if QL is not met or justified.

    Providers should submit quantity justification per plan guidance.

    Formulary coverage rows / Utilization controls

    Coverage and utilization controls are listed per product as Tier = X and Requirements/Limits = Y:

    Examples: Formulary rows specify tier placement and any Requirements/Limits. Example items: AVONEX products listed Tier 5; dalfampridine ER 10 mg Tier 3 requires PA/EDS; dimethyl fumarate Tier 2 with QL 60 per 30 days; DUPIXENT Tier 5 requires PA; OTEZLA Tier 5 requires PA; diclofenac gel requires PA but PA not required for certain specialists (dermatologists/oncologists).

    Each line in the formulary indicates the operational controls that must be met for coverage.

    Formulary coverage with utilization controls

    Formulary coverage is indicated by listing drug, strength, Tier and any Requirements/Limits; coverage requires meeting the noted Requirements/Limits for each product.

    General coverage condition: A drug is covered at the listed formulary tier only when the prescriber and patient meet any Requirements/Limits shown on the same line (e.g., PA, QL, EDS, LA, ENH, BD).

    See the specific formulary line for product-level controls; absence from the list may indicate non-coverage unless an exception is granted.

    Formulary placement and utilization controls

    Formulary placement and utilization controls — how to read the table:

    Tier and controls apply: Products listed with a Tier number are placed on the formulary at that tier. If the Requirements/Limits field for that product lists PA, QL, EDS, LA, or ENH, those utilization management controls apply and must be satisfied for coverage.

    Specific medical necessity criteria and payer PA forms are not included in this excerpt; consult the plan's PA process and the formulary legend (page VII) for operational definitions.

    If a drug is not listed on the formulary and an exception is not granted, Independent Health will not cover the drug. Members should contact Member Services to confirm coverage and may either request a list of covered therapeutic alternatives to discuss with their prescriber or submit a formal exception request for Independent Health to consider.

    Drugs labeled with ENH in the Requirements/Limits column are not normally covered under the Medicare Prescription Drug Plan. Amounts paid for ENH drugs do not count toward total drug costs and are not eligible for Extra Help.

    The content shown in these chunks is a table-of-contents style listing of formulary line items and requirement flags. It does not contain full medical necessity criteria, prior authorization forms, or detailed exclusion language; those detailed criteria are provided elsewhere in the plan materials.

    WEGOVY entries in the formulary are listed with a Requirements/Limits note that includes "Not covered for weight management" for the strengths shown, along with prior authorization and quantity limit annotations.

    The formulary lines for isotretinoin products indicate differing formulary statuses: the document notes "Accutane generic covered, Absorica generic is non-formulary" (and shows Absorica and related isotretinoin entries). This reflects that one generic/formulation may be covered while another brand or generic formulation is non‑formulary.

    No explicit exclusion lists are present in these excerpts. The absence of a product from the displayed lines, or lack of an explicit exclusion statement here, does not imply automatic coverage; full coverage/exclusion determinations require consulting the complete formulary and supporting plan documents.

    Within the provided chunks there are no explicit "not medically necessary" statements for individual products. The excerpt lists tiers and program flags (PA, QL, EDS, LA, ENH) but does not include product-specific 'not medically necessary' determinations.

    What Prescribers and Pharmacies Must Do

    Prior Authorization

    Prior authorization required for PA‑flagged drugs

    Certain drugs listed on the formulary require prior authorization (PA) before the plan will cover them. The Requirements/Limits column of the formulary identifies PA-designated products and the 'Are there any restrictions on my coverage?' section explains that failure to obtain PA may result in noncoverage.

    • Check the Requirements/Limits column for 'PA' before prescribing or dispensing.
    • Obtain prior authorization per Independent Health procedures to avoid claim denial or member financial liability.
    Prior Authorization

    PA applies to listed products (examples: ARIKAYCE, topical/patch items)

    Drugs with 'PA' in the Requirements/Limits column require prior authorization for coverage; examples in the formulary include ARIKAYCE (marked 'PA; LA') and several topical and patch products listed with PA.

    • Verify PA designation on each product line (e.g., ARIKAYCE PA; LA).
    • Follow the plan's PA submission process for these listed products.
    Prior Authorization

    Prior authorization indicated by 'PA' or 'PA New Starts'

    Some formulary entries are labeled 'PA' or 'PA New Starts,' indicating prior authorization is required either for coverage generally or specifically for new therapy starts; prescribers must submit PA requests per the plan's process.

    • For products marked 'PA New Starts', obtain PA prior to initiating therapy.
    • For products marked 'PA' (without 'New Starts'), obtain PA as specified on the product line.
    Prior Authorization

    PA New Starts required for select products (examples: ZTALMY, nasal agents)

    Certain products in the formulary are designated 'PA New Starts' (e.g., ZTALMY oral suspension, some nasal seizure rescue products) which requires prescribers to obtain prior authorization when initiating therapy; some entries note specialty exceptions for neurologists.

    • Obtain PA for new starts of 'PA New Starts' products before dispensing.
    • If prescriber is a neurologist, confirm whether the formulary exempts that specialty for specific nasal products (e.g., NAYZILAM/VALTOCO notes).
    Prior Authorization

    Prior authorization required for various listed drugs

    Multiple specific products are marked 'PA' in the Requirements/Limits column and therefore require prior authorization for coverage (examples include several promethazine formulations and other listed items).

    • Review each formulary line for PA flags and any conditional notes (e.g., age exceptions).
    • Submit PA documentation as required to support medical necessity.
    Prior Authorization

    PA New Starts required for many oral oncology agents

    Many oral oncology agents are labeled 'PA New Starts' in the formulary, indicating prior authorization is required when initiating these therapies and that claims for new starts may be denied without PA.

    • Obtain prior authorization before initiating oral oncology agents flagged 'PA New Starts'.
    • Expect PA to be required for numerous high‑cost oral oncology products listed on Tier 5.
    Prior Authorization

    Prior authorization required for specified products (examples: MAVYRET, PREVYMIS)

    Selected high‑tier products listed with 'PA' (e.g., MAVYRET, PREVYMIS) require prior authorization before coverage will be approved; prescribers should submit PA per plan instructions.

    • Confirm PA status on the product line (e.g., PREVYMIS marked 'PA').
    • Provide necessary clinical information to support the PA request.
    Prior Authorization

    Prior authorization and combined control flags apply

    Products labeled 'PA New Starts' or otherwise marked 'PA' or 'PA; QL' require prior authorization; some entries also pair PA with other controls such as quantity limits or limited access (LA).

    • If a product shows combined flags (e.g., 'PA; QL'), meet both PA and QL conditions to avoid denial.
    • Check for LA (limited access) or other site restrictions on the same line.
    Prior Authorization

    PA required for multiple specialty/high‑cost agents

    Multiple listed drugs show 'Requirements/Limits = PA' on their formulary line (examples include eltrombopag, RETACRIT, UDENYCA, VOYDEYA), and prior authorization must be obtained for these products before coverage.

    • Obtain PA for hematology and other specialty agents flagged 'PA'.
    • Include diagnosis and prior therapy documentation with the PA when required.
    Prior Authorization

    Prior authorization required for select high‑tier products (examples listed)

    Certain high‑tier and specialty products (WEGOVY, KERENDIA, REPATHA formulations, JUXTAPID and others) carry PA or 'PA New Starts' flags; prescribers must secure PA per the formulary to obtain coverage.

    • Check the product line for PA or 'PA New Starts' prior to prescribing.
    • For REPATHA and similar injectables, PA is commonly required for new starts.
    Prior Authorization

    PA required for specified specialty drugs (DUPIXENT, OTEZLA, PANRETIN, etc.)

    Several specialty medications (e.g., DUPIXENT, OTEZLA, PANRETIN, methoxsalen, deferasirox formulations) are listed with 'PA' or 'PA New Starts' in the Requirements/Limits column and require prior authorization before coverage.

    • Submit PA requests for these agents with clinical justification and any required forms.
    • Check for associated LA or QL flags on the same formulary lines.
    Prior Authorization

    Prior authorization required for multiple listed products (see formulary lines)

    Prior authorization (PA) is required for multiple listed products (examples: deferasirox soluble tablets, LINZESS strengths, XIFAXAN 550 mg, BYLVAY, GATTEX, EVRYSDI) — follow the PA process for each PA‑flagged line and note any QL or LA designations.

    • Review the Requirements/Limits field on each product line for PA, QL, LA, or EDS.
    • Provide supporting documentation (diagnosis, prior therapies) as part of the PA submission.
    Prior Authorization

    PA required for listed PA items (RIVFLOZA, CORTROPHIN GEL, testosterone products)

    Several high‑tier or specialty products (e.g., RIVFLOZA, CORTROPHIN GEL, INCRELEX, various testosterone formulations) are marked 'PA' and require prior authorization for coverage; some also list EDS or LA.

    • Obtain PA for CORTROPHIN, RIVFLOZA and listed specialty hormonal products before dispensing.
    • When EDS is present alongside PA, include evidence and any edit‑related documentation requested by the plan.
    Step Therapy

    Step therapy applies to ST‑designated drugs

    Some drugs are subject to step therapy (marked 'ST' in the Requirements/Limits column); prescribers must follow the plan's step therapy rules and document attempts and failures on preferred agents before coverage of step‑required alternatives is approved.

    • Check for 'ST' on the formulary line and follow the step sequencing described in the plan materials.
    • Include documentation of prior treatment trials and outcomes when requesting PA or exceptions for ST‑designated drugs.
    Step Therapy

    Follow step therapy (ST) rules for ST‑flagged products

    Drugs listed with 'ST' in Requirements/Limits are subject to step therapy; the formulary and the 'Are there any restrictions on my coverage?' section describe that the member may need to try preferred drugs first before alternatives are covered.

    • Verify ST designation and ensure prior trial of preferred agent(s) is documented.
    • If requesting an exception to step therapy, prescriber must provide medical rationale per the exception process.
    Note

    Step edits and other utilization management implied by EDS / PA New Starts / LA

    Some formulary entries include 'EDS', 'PA New Starts; LA' or other edit flags that imply utilization management like step edits, limited access, or evidence/documentation requirements; prescribers should submit required evidence to avoid edit‑related denials.

    • When a product shows 'EDS', expect plan edits and include supporting documentation to satisfy evidence requirements.
    • Products with 'PA New Starts; LA' may have limited availability and require PA plus site‑of‑care justification.
    Prior Authorization

    Combined prior authorization and quantity‑limit controls (PA New Starts; QL)

    Some products combine prior authorization and quantity limits (e.g., entries showing 'PA New Starts; QL' such as EXXUA), requiring prescribers to secure PA and to adhere to QL thresholds when prescribing.

    • For products marked with both PA and QL, submit PA that documents the clinical need for requested quantity.
    • Anticipate claim edits if QL is exceeded without PA.
    Step Therapy

    Step therapy or PA New Starts apply to certain agents

    Some agents carry 'ST' or 'PA New Starts' flags (for example febuxostat is marked 'ST' and many oncology/antiandrogen agents are 'PA New Starts'), indicating that either a prior step is required or PA is required for new therapy starts.

    • Confirm whether ST or PA New Starts applies on the product line before prescribing.
    • Document prior therapies (for ST) or obtain PA for new starts as required.
    Prior Authorization

    Prior authorization required — check formulary flags and legend

    Prior authorization is required for many listed products; the formulary flags (PA, PA New Starts) and the 'Are there any restrictions on my coverage?' section instruct prescribers to obtain authorization to prevent denial of coverage.

    • Always check the Requirements/Limits field and obtain required PA prior to dispensing.
    • If unsure, contact Independent Health Member Services or consult the formulary index and legend (page VII) for definitions.
    Denial Risk

    Denial risk if prior authorization not obtained

    Failure to obtain required prior authorization for PA‑flagged drugs may result in the plan not covering the drug or the member being liable for cost; obtain PA and submit necessary clinical documentation to avoid denial.

    • Obtain PA before dispensing PA‑flagged items for new starts and ongoing therapy when required.
    • Advise members that coverage may be denied without PA and that they can request an exception if clinically indicated.
    Documentation Required

    Provide setting/use info for Part B vs Part D determinations (BD flag)

    If a drug's coverage is determined to fall under Medicare Part B rather than Part D (BD flag), submission of information about the drug's use and setting may be required; if Part B coverage is found, the drug will not be covered under the Part D tier listing.

    • Provide setting/use details when requested to allow the plan to determine Part B vs Part D coverage.
    • Do not assume Part D tier cost‑sharing applies if BD is indicated; verify with Member Services or Evidence of Coverage.
    Denial Risk

    PA/QL/EDS/LA flags may trigger restrictions or denials

    Products flagged 'PA', 'QL', 'EDS', or 'LA' may trigger coverage restrictions, edits, or denials if the specified program requirements are not met; prescribers should follow the formulary's Requirements/Limits for each listed product.

    • When a product shows QL, ensure the quantity requested does not exceed the listed limit or include PA to justify overage.
    • When EDS appears, include required evidence or anticipate edit‑based review.
    Prior Authorization

    PA required for new therapy starts ('PA New Starts')

    Products labeled 'PA New Starts' (e.g., many oncology oral agents, ZTALMY, some nasal rescue products) require prior authorization when initiating therapy; claims for new starts may be denied without PA.

    • Secure PA before starting treatment with 'PA New Starts' drugs.
    • Document that the prescription represents a new start when submitting PA.
    Documentation Required

    Documentation and quantity edits can trigger claim denials

    Products with EDS (evidence/edit standard) or QL (quantity limit) may be subject to claim edits or automatic rejection if documentation is missing or the requested quantity exceeds the listed limit; include quantity justification and supporting clinical documentation with PA or exception requests.

    • Provide quantity and clinical rationale when requesting amounts above QL.
    • For EDS entries, include evidence of medical necessity per plan requirements.
    Note

    Follow formulary requirement flags (PA, QL, EDS, ST, LA) to avoid denials

    Formulary requirement flags (PA, QL, EDS, BD, ST, LA) across the drug list indicate specific utilization controls and denial risks; prescribers must follow the flagged requirements to avoid coverage denial.

    • Consult the legend (page VII) for precise meanings of each flag before submitting PA or exception requests.
    • Address every flagged requirement on the product line when completing authorizations.
    Denial Risk

    Quantity limits overage and denial triggers

    Exceeding stated quantity limits (e.g., Paxlovid pack QLs or sacubitril‑valsartan QL entries) or failing to meet PA/LA/EDS/ST requirements may result in denial or override; check the QL shown on each product line and obtain PA when requesting amounts above the limit.

    • Compare the requested supply to the product's QL (e.g., Paxlovid pack QLs per 365 days).
    • If over QL, submit PA with clinical justification or request an exception.
    Prior Authorization

    PA required for PA‑coded drugs (examples: eltrombopag, RETACRIT, UDENYCA)

    Products flagged 'PA' or 'PA; QL' (for example eltrombopag, RETACRIT, UDENYCA, VOYDEYA) require prior authorization; claims submitted without the required PA may be denied.

    • Obtain PA for products with PA or PA; QL flags prior to dispensing.
    • Include QL‑related justification when PA covers quantities above the listed limit.
    Prior Authorization

    PA required entries (examples: WEGOVY, KERENDIA)

    Coverage may be denied for listed products (e.g., WEGOVY, KERENDIA) where the line indicates 'PA' or 'PA New Starts'; verify PA status and obtain authorization to prevent claim denial.

    • Check the product line for PA or PA New Starts before prescribing.
    • Submit clinical documentation as required by the plan's PA process.
    Denial Risk

    Quantity limit overage may trigger denial

    Exceeding quantity limits specified on formulary lines (e.g., sacubitril‑valsartan 60 EA/30 days, VASCEPA/icosapent ethyl QLs) may cause claim rejection or require PA; adhere to QL values or seek authorization for overages.

    • Confirm QL values on each product line before prescribing.
    • Request PA and provide justification if a higher quantity is clinically necessary.
    Prior Authorization

    PA required for certain specialty agents (e.g., DUPIXENT)

    Some specialty/high‑tier agents (e.g., DUPIXENT auto‑injector and prefilled syringe) are PA‑flagged; prior authorization must be obtained for these specialty agents to receive coverage.

    • Submit PA for specialty biologics, including brand and formulation details (auto‑injector vs prefilled syringe).
    • Include clinical indication and prior therapy documentation as required.
    Documentation Required

    EDS and QL edit requirements may trigger denials (examples provided)

    Entries marked 'EDS' or 'QL' denote plan edits or quantity limits that require fulfillment of edit criteria or documentation; failure to meet these could result in denial (examples: dimethyl fumarate QL 60 EA per 30 days; teriflunomide 7 mg QL 30 EA per 30 days).

    • Provide required evidence and adhere to specified QL to avoid claim edits.
    • If edits block the claim, submit PA or exception with supporting clinical information.
    Denial Risk

    Failure to meet Requirements/Limits can lead to denial

    Coverage may be denied if prior authorization (PA) or other program‑specific requirements (LA, BD, EDS) listed for a product are not met; prescribers should follow the Requirements/Limits field on each formulary line.

    • Before prescribing, review the product's Requirements/Limits and obtain PA or other documentation as indicated.
    • Advise members about potential coverage denial if requirements are unmet and about exception processes.
    Denial Risk

    High‑tier (Tier 4–5) drugs require adherence to PA/QL/EDS/LA conditions

    High‑tier drugs (Tiers 4–5) often include Requirements/Limits such as PA, LA, QL, or EDS; claims for these high‑cost items risk denial if those conditions are not satisfied.

    • Anticipate PA and additional documentation for Tier 4–5 medications.
    • Use the exception/tiering request process when clinically justified to seek coverage or lower cost‑sharing.
    Denial Risk

    Denial risk when PA/QL/EDS requirements are not met

    Claims for products listed with PA, QL, or EDS may be denied if those requirements are unmet; prescribers should include required documentation (diagnosis, prior therapies, quantity justification) in PA or exception submissions.

    • Follow PA/EDS procedures and provide medical necessity documentation to support requests.
    • Use the formulary legend (page VII) and the plan's PA forms to ensure submissions meet requirements.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Drug Entries and Coding Notes

    Selected listed drugs with tiers and requirementsNDC | plain_text
    ARIKAYCE INHALATION SUSPENSION 590 MG/8.4MLTier = 5; Requirements/Limits = PA; LA
    VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MGTier = 5
    KLOXXADO NASAL LIQUID 8 MG/0.1MLTier = 3
    OPVEE NASAL SOLUTION 2.7 MG/0.1MLTier = 3
    linezolid oral suspension reconstituted 100 mg/5mlTier = 5
    daptomycin intravenous solution reconstituted 500 mgTier = 5
    Additional noted product (no NDC provided)mixed
    NDCs not providedProduct names, strengths, tiers and Requirements/Limits are listed in the formulary table; NDCs are not included in these chunks.
    Opioid analgesics entries with quantity limitsplain_text
    buprenorphine transdermal patch weekly 10 mcg/hr, 15 mcg/hr, 5 mcg/hr, 7.5 mcg/hrTier = 4; QL (4 EA per 28 days)
    fentanyl transdermal patch 72 hour 100 mcg/hr, 75 mcg/hrTier = 4; QL (30 EA per 30 days)
    fentanyl transdermal patch 72 hour 12 mcg/hr, 25 mcg/hr, 50 mcg/hrTier = 4; QL (15 EA per 30 days)
    hydrocodone bitartrate er oral tablet abuse-deterrentTier = 4; QL (30 EA per 30 days)
    methadone hcl oral tablet 5 mg and 10 mgTier = 2; methadone hcl oral tablet 5 mg Requirements/Limits = QL (240 EA per 30 days); 10 mg listed Tier = 2
    tramadol hcl er oral tablet 100 mg, 200 mgTier = 4; QL (30 EA per 30 days)
    Opioid product lines without NDCsmixed
    NDCs not providedFormulary presents product lines and QL examples; billing codes/NDCs are not listed in these chunks.
    Formulary drug list entries (no billing codes provided in this excerpt)mixed
    No codes listed
    NDC/HCPCS not listed — product lines onlymixed
    No codes listed
    NDC/CPT/HCPCS not listed in these chunksmixed
    No codes listed
    Formulary drug entries (no billing codes provided in this excerpt)NDC | mixed
    No codes listed
    Formulary product entries (no billing codes present)mixed
    NDCs not providedThe document lists product names, strengths, packaging, tiers and Requirements/Limits but does not include NDC or CPT/ICD codes in these chunks.
    Potassium and electrolyte products (examples)plain_text
    potassium chloride intravenous solution (various concentrations)Tier = 2; Requirements/Limits may vary
    potassium chloride oral packet 20 meqTier = 2; Requirements/Limits = EDS
    potassium chloride oral solution 20 meq/15mlTier = 2; Requirements/Limits = EDS
    Deferasirox and relatedplain_text
    deferasirox oral tablet 180 mg, 360 mg, 90 mgTier = 3; Requirements/Limits = EDS
    deferasirox oral tablet soluble 125 mgTier = 4; Requirements/Limits = PA; EDS
    deferasirox oral tablet soluble 250 mg, 500 mgTier = 5; Requirements/Limits = PA
    Tolvalptan and related electrolytesplain_text
    tolvaptan (hyponatremia) oral tablet 15 mgTier = 5; Requirements/Limits = PA; QL (30 EA per 30 days)
    tolvaptan oral tablet 30 mgTier = 5; Requirements/Limits = PA
    tolvaptan oral tablet therapy pack (various)Tier = 5; Requirements/Limits = PA; QL (60 EA per 30 days)
    LINZESS and GI agentsplain_text
    LINZESS ORAL CAPSULE 145 MCG, 72 MCGTier = 3; Requirements/Limits = QL (30 EA per 30 days); EDS
    LINZESS ORAL CAPSULE 290 MCGTier = 3; Requirements/Limits = EDS
    XIFAXAN entriesplain_text
    XIFAXAN ORAL TABLET 200 MGTier = 4; Requirements/Limits = QL (9 EA per 3 days)
    XIFAXAN ORAL TABLET 550 MGTier = 5; Requirements/Limits = PA
    Sildenafil / Tadalafil (Genitourinary)plain_text
    sildenafil citrate oral tablet 100 mg, 25 mg, 50 mgTier = 2; Requirements/Limits = ENH; QL (10 EA per 30 days)
    tadalafil oral tablet 10 mg, 20 mg (ed)Tier = 2; Requirements/Limits = ENH; QL (6 EA per 30 days)
    Selected product entries (drug descriptions as listed)NDC | mixed
    RIVFLOZA SUBCUTANEOUS SOLUTION 80 MG/0.5MLlisted product and strength
    RIVFLOZA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 128 MG/0.8ML, 160 MG/MLlisted product and strengths
    CORTROPHIN GEL SUBCUTANEOUS PREFILLED SYRINGE 40 UNIT/0.5ML, 80 UNIT/MLlisted product and strengths
    INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4MLlisted product and strength
    LILETTA (52 MG) INTRAUTERINE DEVICE 20.1 MCG/DAYlisted IUD product and release rate
    Formulary note (no codes)mixed
    NDCs not providedThese product entries list formulations, tiers and PA/QL/LA flags but do not include billing codes in the cited chunks.
    Testosterone formulationsmixed
    testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)various formulations and strengths listed; Requirements/Limits = PA; EDS for many entries
    Testosterone additional lines (no NDCs)mixed
    testosterone transdermal gel 20.25 mg/act (1.62%)Tier = 2; Requirements/Limits = PA; EDS
    testosterone transdermal solution 30 mg/actTier = 4; Requirements/Limits = PA; EDS
    Quantity limits examples — inv-23
    QL (4 EA per 28 days)Buprenorphine transdermal patch (weekly 10,15,5,7.5 mcg/hr) — Requirements/Limits = QL (4 EA per 28 days)
    QL (30 EA per 30 days)Fentanyl transdermal patch 72 hr (100 mcg/hr, 75 mcg/hr) — Requirements/Limits = QL (30 EA per 30 days)
    QL (240 EA per 30 days)Methadone HCl oral tablet 5 mg and 10 mg — some strengths shown with QL (240 EA per 30 days)
    Quantity limits examples — inv-24
    QL (30 EA per 30 days)VRAYLAR oral capsule (all strengths) — Requirements/Limits = QL (30 EA per 30 days)
    QL (80 EA per 365 days)PAXLOVID therapy pack (certain pack) — Requirements/Limits = QL (80 EA per 365 days)
    QL (44 EA per 365 days)PAXLOVID therapy pack (6x150 & 5x100) — Requirements/Limits = QL (44 EA per 365 days)
    QL (120 EA per 365 days)PAXLOVID therapy pack (20x150 & 10x100) — Requirements/Limits = QL (120 EA per 365 days)
    Quantity limits examples — inv-25
    QL (3 ML per 28 days)OZEMPIC subcutaneous solution pen-injector (various strengths) — Requirements/Limits = QL (3 ML per 28 days)
    QL (2 ML per 28 days)MOUNJARO subcutaneous solution auto-injector (selected strengths) — Requirements/Limits = QL (2 ML per 28 days)
    QL (60 EA per 365 days)RYBELSUS (oral semaglutide) 3 mg formulation R2 — Requirements/Limits = QL (60 EA per 365 days)
    QL (30 EA per 30 days)Multiple oral/other products (examples in table) — e.g., repaglinide 150 EA per 30 days listed elsewhere; representative QL = 30 EA per 30 days
    QL (15 EA per 30 days)Omnipod pods and certain device supplies — Requirements/Limits example = QL (15 EA per 30 days)
    Quantity limits examples — inv-26
    QL (60 EA per 30 days)Sacubitril-valsartan oral tablet (24-26 mg, 49-51 mg) — Requirements/Limits = QL (60 EA per 30 days)
    QL (30 EA per 30 days)KERENDIA oral tablet (10,20,40 mg) — Requirements/Limits = QL (30 EA per 30 days)
    QL (120 EA per 30 days)Icosapent ethyl (VASCEPA) oral capsule 0.5 gm — Requirements/Limits = QL (120 EA per 30 days)
    QL (50-70 ML per 28 days)RADICAVA ORS oral suspension 105 mg/5 mL — Requirements/Limits = QL (50 ML per 28 days) and starter kit QL (70 ML per 28 days)
    Quantity limits examples — inv-27
    QL (60 EA per 30 days)Dimethyl fumarate oral capsule delayed release 120 mg — Requirements/Limits = QL (60 EA per 30 days)
    QL (30 EA per 30 days)Teriflunomide oral tablet 7 mg — Requirements/Limits = QL (30 EA per 30 days)
    Quantity limits examples — inv-28
    QL (10 EA per 30 days)Sildenafil citrate oral tablet — Requirements/Limits = QL (10 EA per 30 days)
    QL (6 EA per 30 days)Tadalafil oral tablet (ED) — Requirements/Limits = QL (6 EA per 30 days)
    QL (600 ML per 30 days)EOHILIA oral suspension 2 mg/10 mL — Requirements/Limits = QL (600 ML per 30 days)
    QL (8 EA per 28 days)Estradiol transdermal patch (twice-weekly formulations) — Requirements/Limits = QL (8 EA per 28 days)
    QL (4 EA per 28 days)Estradiol transdermal patch (weekly formulations) — Requirements/Limits = QL (4 EA per 28 days)

    Step Therapy & 'PA New Starts' Controls

    Drug / ProductRequirement (ST flag)
    General — formulary step therapy policy (ST indicates step therapy applies)
    See formulary 'Requirements/Limits' column for specific products marked 'ST'
    What ST meansProvider action / Reference
    'ST' in Requirements/Limits indicates the product is subject to step therapy (try specified preferred drug(s) first)
    Follow the formulary's step therapy rules described under 'Are there any restrictions on my coverage?' and the Requirements/Limits column
    Anticonvulsant product(s)Requirement / Flag shown
    DIACOMIT (stiripentol) — oral capsule/packet entriesPA New Starts; LA
    EPIDIOLEX (cannabidiol) — oral solutionPA New Starts; LA
    LEVETIRACETAM / LAMOTRIGINE / other anticonvulsants (selected strengths) — various entriesEDS or PA New Starts indicated on some lines
    ProductRequirement / Note
    EXXUA (and EXXUA titration pack)Requirements/Limits = PA New Starts; QL shown — implies prior authorization required for new starts; explicit step sequence not provided in excerpt
    ProductRequirement
    febuxostat (listed among antigout agents)Requirements/Limits = ST (step therapy applies)
    Oncology / antiandrogen examplesRequirement / Flag
    Abiraterone acetate, bicalutamide, abiraterone-class agents (antiandrogens)Requirements/Limits = PA New Starts
    Lenalidomide, pomalidomide, other antineoplasticsRequirements/Limits = PA New Starts (many oncology oral agents flagged)
    Various oral oncology agents (multiple listings)Requirements/Limits = PA New Starts; some also LA or QL
    Context / common pairingExample flags
    Prior authorization for new starts is frequently paired with other utilization controlsCommon combined flags: 'PA New Starts' with LA (limited access) or QL (quantity limit); EDS may also appear
    ProductRequirement
    VERSACLOZ oral suspension 50 mg/mLRequirements/Limits = ST (step therapy) indicated
    GLP-1 / oral GLP productsRequirement / Note
    OZEMPIC (semaglutide) subcutaneous pen-injectorRequirements/Limits = PA New Starts; QL; EDS — prior authorization for new starts noted; no multi-step algorithm shown in excerpt
    MOUNJARO (tirzepatide) subcutaneous auto-injector and RYBELSUS (oral semaglutide)Requirements/Limits = PA New Starts; QL; EDS — PA New Starts indicated, explicit step sequencing not provided in excerpt
    ProductRequirement
    aliskiren fumarate (listed in cardiovascular agents)Requirements/Limits = ST (step therapy applies)
    Specialty / high-cost examplesRequirement / Flag
    REPATHA (various presentations) — PCSK9 inhibitorsRequirements/Limits = PA New Starts; EDS (management for new starts and edits)
    RADICAVA ORS, SKYCLARYS, AUSTEDO and other specialty CNS agentsRequirements/Limits = PA New Starts; LA; QL as listed
    Multiple other specialty oral oncology agentsRequirements/Limits = PA New Starts; LA (limited access) often present
    ProductRequirement / Example
    PANRETIN external gel 0.1%Requirements/Limits = PA New Starts (prior authorization required for new starts)
    Product / ExampleImplication
    ATTRUBY and similar specialty/genetic disorder therapies (examples in document)Requirements/Limits include 'New Starts' or 'LA' which imply origin or access restrictions for coverage; explicit step therapy algorithms not shown in excerpt
    Product examplesEDS implication
    Desmopressin, estradiol patches, selected testosterone formulations (examples listed)Requirements/Limits = EDS — indicates formulary edits/step requirements apply; prescriber documentation or prior use of preferred alternatives may be required

    Quantity Limits (QL) — Examples and Line Items

    Digoxin quantity example (inv-126)
    Digoxin example: 30 tablets per prescriptionIndependent Health provides 30 tablets per prescription for digoxin 125 mcg as an illustrative quantity limit in the 'Are there any restrictions on my coverage?' section.
    Digoxin formulary QLsFormulary rows show digoxin 62.5 mcg listed with QL 30 EA per 30 days and digoxin 125 mcg noted with example prescription limits (35 EA per 30 days in product table).
    Prescriber exceptions notedSome digoxin entries note prior authorization not required for cardiologists for specific formulations (see formulary lines).
    Fentanyl and buprenorphine patch quantity limits (inv-127)
    Fentanyl patch QL (30 EA per 30 days)Fentanyl transdermal patch 72-hour strengths (100/75 mcg/hr) are listed with QL 30 EA per 30 days in the formulary table.
    Fentanyl patch QL (15 EA per 30 days)Lower-strength fentanyl patches (12/25/50 mcg/hr) are listed with QL 15 EA per 30 days as a separate QL rule.
    Buprenorphine patch QL (4 EA per 28 days)Buprenorphine transdermal patch weekly (10/15/5/7.5 mcg/hr) is listed with QL 4 EA per 28 days in the table.
    Buprenorphine patch weekly quantity limit (inv-128)
    Buprenorphine transdermal patch weekly QL = 4Buprenorphine transdermal patch weekly (10/15/5/7.5 mcg/hr) is limited to 4 EA per 28 days as shown in the formulary table.
    Related opioid patch QLsThe opioid analgesics section groups similar patch QLs (fentanyl and buprenorphine entries appear with separate QL rules).
    Tiering notedThese patch products are typically Tier 4 with the QL indicated in the Requirements/Limits column.
    Fosfomycin tromethamine packet QL (inv-129)
    Fosfomycin tromethamine 3 g QL = 1Fosfomycin tromethamine oral packet 3 gm is listed with a quantity limit of 1 (1 EA per 30 days) in the formulary table.
    Tier assignmentFosfomycin packet is listed at Tier = 4 in the formulary rows where the QL is shown.
    Per-period unitThe formulary explicitly notes the QL as '1 EA per 30 days' for the 3 g packet presentation.
    Fosfomycin QL per 30 days (inv-130)
    Fosfomycin tromethamine QL = 1 EA per 30 daysThe product line for fosfomycin tromethamine oral packet 3 gm shows Requirements/Limits = QL (1 EA per 30 days) in the table.
    Formulary tierListed as Tier = 4 where the QL is displayed.
    QL period specifiedThe quantity limit is explicitly tied to a 30-day period in the Requirements/Limits column.
    Brivaracetam quantity limits (inv-131)
    Brivaracetam QL (240 EA per 30 days)Some strengths of brivaracetam oral tablet are limited to QL 240 EA per 30 days as shown in the formulary table.
    Brivaracetam QL (60 EA per 30 days)Other brivaracetam strengths are limited to QL 60 EA per 30 days depending on presentation.
    Tier and PA flagsBrivaracetam strengths appear with differing requirements/limits; review the specific line for the applicable QL and any PA/EDS flags.
    Perampanel quantity limit (inv-132)
    Perampanel QL (30 EA per 30 days)Perampanel oral tablets (selected strengths) are listed with QL 30 EA per 30 days in the formulary table.
    Multiple strengthsSome perampanel presentations (e.g., 2 mg) carry the same QL; check the specific line for exact QL assignment.
    Tier assignmentsPerampanel entries are assigned to Tier 4–5 depending on formulation; QL is shown in Requirements/Limits column.
    Perampanel tablets quantity limit (inv-133)
    Perampanel tablets QL = 30 EA per 30 daysPerampanel oral tablets (multiple strengths) are limited to 30 EA per 30 days per the formulary Requirements/Limits column.
    EDS notesSome perampanel presentations also include EDS in addition to QL for dispensing/edit purposes.
    TieringPerampanel is listed at higher tiers (Tier 4–5) consistent with specialty antiepileptic agents.
    XCOPRI therapy pack QL (inv-134)
    XCOPRI therapy pack QL (56 EA per 28 days)XCOPRI (250 mg daily dose) oral tablet therapy packs are listed with QL 56 EA per 28 days in the formulary table.
    Multiple pack strengthsXCOPRI has several pack presentations (100/150/200 mg) with QLs noted per pack type; check the exact therapy pack line for the applicable QL.
    TieringXCOPRI therapy packs are placed at Tier 4–5 depending on the daily dose/pack configuration.
    EXXUA quantity limit (inv-135)
    EXXUA QL (30 EA per 30 days)EXXUA is listed with Requirements/Limits = PA New Starts; QL (30 EA per 30 days) indicating combined PA and quantity limit controls.
    Titration pack noteEXXUA titration pack also appears with PA New Starts and a pack-specific QL in adjacent formulary lines.
    TierEXXUA is assigned Tier = 5 in the formulary where the QL and PA New Starts flags appear.
    VIVJOA therapy pack QL (inv-136)
    VIVJOA therapy pack QL (18 EA per 84 days)VIVJOA oral capsule therapy pack 150 mg is listed with Requirements/Limits = PA; QL (18 EA per 84 days) in the formulary table.
    PA requirementVIVJOA is also marked PA in the Requirements/Limits column, indicating prior authorization is required for coverage.
    TierVIVJOA appears at Tier = 4 in the formulary entries shown.
    SIRTURO entry (inv-137)
    SIRTURO QL/PASIRTURO oral tablet is listed with Requirements/Limits = PA (see formulary lines).
    Tier assignmentSIRTURO appears at Tier = 5 in the formulary table where PA is indicated.
    Use contextSIRTURO is included among antitubercular agents with PA indicated for coverage.
    OGSIVEO quantity limit (inv-138)
    OGSIVEO QL (60 EA per 30 days)OGSIVEO oral tablet 100/150 mg is listed with Requirements/Limits = PA New Starts; LA; QL (60 EA per 30 days).
    PA New Starts and LAOGSIVEO's line shows both PA New Starts and Limited Access (LA) in addition to the QL.
    TierOGSIVEO is assigned Tier = 5 in the formulary entries where these limits are shown.
    VORANIGO quantity limit (inv-139)
    VORANIGO QL (60 EA per 30 days)VORANIGO oral tablet 10 mg is listed with Requirements/Limits = PA New Starts; QL (60 EA per 30 days).
    Additional strengthsHigher-strength VORANIGO presentations are also listed with PA New Starts; check specific line for QL applicability.
    TierVORANIGO entries are placed at Tier = 5 in the formulary table.
    FRUZAQLA quantity limits (inv-140)
    FRUZAQLA QL (120 EA per 30 days)FRUZAQLA oral capsule 1 mg is listed with Requirements/Limits = PA New Starts; LA; QL (120 EA per 30 days).
    Alternate FRUZAQLA QL (30 EA per 30 days)FRUZAQLA 5 mg presentation shows QL 30 EA per 30 days on a separate line.
    TierFRUZAQLA is assigned Tier = 5 and flagged PA New Starts and LA where QLs appear.
    LYTGOBI therapy pack QL (inv-141)
    LYTGOBI therapy pack QL (84 EA)LYTGOBI therapy packs are listed with QL 84 (EA per 28 days) where shown in the formulary table.
    PA/LA flagsLYTGOBI therapy packs commonly accompany PA New Starts and LA designations in adjacent cancer therapy lines.
    TierLYTGOBI appears at Tier = 5 in the formulary entries with QL noted.
    RUBRACA quantity limit (inv-142)
    RUBRACA QL (120 EA per 30 days)RUBRACA oral tablet (some strengths) is listed with QL 120 EA per 30 days in the therapy table.
    PA New Starts/LA contextRUBRACA lines commonly appear with PA New Starts and LA flags for certain presentations.
    TierRUBRACA is assigned Tier = 5 where the QL is shown.
    TRUQAP therapy pack QL (inv-143)
    TRUQAP therapy pack QL (64 EA per 28 days)TRUQAP oral tablet therapy pack is listed with QL 64 EA per 28 days in the formulary table.
    PA New StartsTRUQAP entries show PA New Starts (and LA on some lines) alongside the QL.
    TierTRUQAP is assigned Tier = 5 in the formulary where the therapy pack QL is specified.
    VITRAKVI quantity limit (inv-144)
    VITRAKVI QL (180 EA per 30 days)VITRAKVI oral capsule 25 mg is listed with Requirements/Limits = PA New Starts; LA; QL (180 EA per 30 days) in the table.
    Multiple presentationsVITRAKVI has multiple capsule and solution presentations with PA New Starts and LA flags; QL applies to select strengths (25 mg example shown).
    TierVITRAKVI is placed at Tier = 5 in the formulary entries where QL appears.
    XPOVIO therapy pack quantity ranges (inv-145)
    XPOVIO therapy pack QLs (4–24 EA per 28 days)XPOVIO therapy packs are listed with variable QLs depending on dosing schedule: examples include 4, 8, 16, and 24 EA per 28 days in the formulary rows.
    PA New Starts/LAXPOVIO therapy packs are flagged PA New Starts and LA in addition to the pack-specific QLs.
    TierXPOVIO therapy packs are assigned Tier = 5 where the QLs are specified.
    VRAYLAR quantity limit (inv-146)
    VRAYLAR QL (30 EA per 30 days)VRAYLAR oral capsule (all strengths) is listed with QL 30 EA per 30 days in the formulary table.
    TierVRAYLAR entries are placed at Tier = 5 where the QL is shown.
    QL periodThe QL is explicitly tied to a 30-day period in the Requirements/Limits column.
    PAXLOVID therapy pack quantity limits (inv-147)
    PAXLOVID therapy pack annual QLsPAXLOVID therapy packs are listed with pack-specific annual quantity limits: e.g., QL 80 EA per 365 days; QL 44 EA per 365 days; QL 120 EA per 365 days depending on pack configuration.
    TierPAXLOVID therapy packs appear at Tier = 3 in the formulary lines where QLs are noted.
    Pack-specific rulesDifferent therapy pack sizes have distinct annual QLs; check the specific pack line for the applicable limit.
    Risperidone dispersible quantity limits (inv-148)
    Risperidone dispersible QLsRisperidone oral tablet dispersible shows QL 90 EA per 30 days for some low strengths and QL 30 EA per 30 days for other strengths as indicated in the table.
    EDS flagThese risperidone dispersible lines also include EDS in the Requirements/Limits column for dispensing guidance.
    TierRisperidone dispersible entries are assigned Tier = 3 where QLs are specified.
    Multiple example quantity limits (inv-149)
    3 ML per 28 daysOZEMPIC pen-injector presentations commonly show QL 3 mL per 28 days for specified strengths.
    2 ML per 28 daysMOUNJARO/TRULICITY and some GLP-1 injectables show QL 2 mL per 28 days for certain strengths/presentations.
    60 EA per 365 daysRYBELSUS 3 mg formulation example shows QL 60 EA per 365 days as an annual limit for that strength.
    30 EA per 30 daysCommon monthly QL across many oral tablet lines (e.g., select GLP-1/antidiabetic or cardiovascular agents).
    15 EA per 30 daysDevice pod or insulin-related QL example (OMNIPOD pods QL 15 EA per 30 days).
    Eltrombopag quantity limit (inv-150)
    Eltrombopag QL (30 EA per 30 days)Eltrombopag olamine oral tablet and packet (12.5 mg, 25 mg) are listed with QL 30 EA per 30 days and PA requirements for select presentations.
    PA flagSome eltrombopag packet/tablet presentations also require PA in addition to the QL.
    TierEltrombopag entries appear at Tier = 5 where PA and QL are applied.
    VOYDEYA therapy pack quantity limit (inv-151)
    VOYDEYA therapy pack QL (180 EA per 30 days)VOYDEYA oral tablet therapy pack (50 & 100 mg) is listed with Requirements/Limits = PA; LA; QL (180 EA per 30 days).
    PA and LA flagsVOYDEYA lines include PA and Limited Access designations in addition to the high QL for therapy packs.
    TierVOYDEYA is assigned Tier = 5 where these therapy-pack QLs are noted.
    CAMZYOS quantity limit (inv-152)
    CAMZYOS QL (30 EA per 30 days)CAMZYOS oral capsule is listed with QL 30 EA per 30 days in the formulary table.
    TierCAMZYOS appears at Tier = 5 in the listing where the QL is shown.
    PA flag if presentSome cardiac specialty agents include PA/EDS flags; check the specific CAMZYOS line for additional limits.
    Digoxin 125 mcg QL example (inv-153)
    Digoxin 125 mcg QL (35 EA per 30 days)Formulary product lines show digoxin oral tablet 125 mcg with a QL of 35 EA per 30 days in the table entries.
    Digoxin 62.5 mcg QL (30 EA per 30 days)Digoxin 62.5 mcg is listed with QL 30 EA per 30 days in the product lines.
    Prescriber exceptionsSome digoxin presentations note PA not required for cardiologists for certain strengths; see the specific row for details.
    Digoxin 62.5 mcg quantity limit (inv-154)
    Digoxin 62.5 mcg QL (30 EA per 30 days)The formulary lists digoxin 62.5 mcg with Requirements/Limits = QL (30 EA per 30 days); EDS may also apply on some lines.
    TieringDigoxin 62.5 mcg appears at Tier = 4 in the formulary rows where the QL is shown.
    Related notesDigoxin 250 mcg lines include PA and specialty prescriber exceptions; consult the specific product line for exact rules.
    Ivabradine quantity limit (inv-155)
    Ivabradine QL (60 EA per 30 days)Ivabradine HCl oral tablet is listed with QL 60 EA per 30 days and PA; prior authorization not required for cardiologists on certain lines.
    PA prescriber exceptionFormulary notes indicate PA not required for cardiologists for specified ivabradine presentations.
    TierIvabradine appears at Tier = 4 where QL and PA are shown.
    Sacubitril-valsartan quantity limit (inv-156)
    Sacubitril-valsartan QL (60 EA per 30 days)Sacubitril-valsartan oral tablets (24-26 mg, 49-51 mg) are listed with QL 60 EA per 30 days in the formulary table.
    EDS flagSome sacubitril-valsartan strengths also include EDS in the Requirements/Limits column.
    TierThese entries are placed at Tier = 3 where the QL is specified.
    VOYDEYA non-therapy pack note (inv-157)
    VOYDEYA non-therapy pack entryVOYDEYA oral tablet 100 mg (non-therapy pack) is listed with PA; LA in the formulary — specific QL for non-pack presentation not shown in this excerpt.
    Therapy pack QL vs non-packTherapy pack presentations have explicit high QLs (e.g., 180 EA per 30 days); single-tablet lines may omit a pack-specific QL.
    TierVOYDEYA non-pack is Tier = 5 where PA/LA are indicated.
    Cardiovascular/CNS quantity limit examples (inv-158)
    Cardiac/metabolic agent QL examplesFormulary shows multiple examples across cardiovascular/metabolic agents: sacubitril-valsartan QL 60 EA/30 days; KERENDIA QL 30 EA/30 days; icosapent ethyl and VASCEPA QL 120 EA/30 days; RADICAVA ORS QL 50–70 mL per 28 days.
    Exceeding QLs may trigger PA/denialThe formulary notes that requests exceeding these listed quantity limits may require prior authorization or be denied.
    EDS interplayMany of these agents also include EDS flags indicating edits or extended-day-supply rules apply alongside QL.
    Dimethyl fumarate quantity limit (inv-159)
    Dimethyl fumarate QL (60 EA per 30 days)Dimethyl fumarate oral capsule delayed release 120 mg is listed with QL 60 EA per 30 days in the Multiple Sclerosis agents section.
    Dimethyl fumarate other strengths240 mg presentation appears with EDS; check the specific line for QL applicability.
    TierDimethyl fumarate entries are placed at Tier = 2 where QL is shown.
    Teriflunomide 7 mg quantity limit (inv-160)
    Teriflunomide 7 mg QL (30 EA per 30 days)Teriflunomide oral tablet 7 mg is specifically listed with QL 30 EA per 30 days in the formulary table.
    EDS flagTeriflunomide lines also show EDS applied on other strengths/presentations in the Multiple Sclerosis section.
    TierTeriflunomide entries are assigned Tier = 3 where QL is specified.
    Inline quantity-limit annotations (inv-161)
    Inline QL annotations (various periods)Several products include inline QL annotations such as 30 EA per 30 days (LINZESS), 9 EA per 3 days (XIFAXAN 200 mg), 12 EA per 3 days (other formulations), 28/56 EA per 28 days (VIJOICE packs), and 60 EA per 30 days (tolvaptan presentations).
    Check specific line for periodThe formulary ties each QL to its specific period (per 3 days, per 28 days, per 30 days, per 365 days); always confirm the exact Requirements/Limits cell for the product.
    PA/EDS interplayMany of these inline QLs coexist with PA, EDS, or LA flags — documentation or prior authorization may be required when exceeding or dispensing at the limit.
    PDE5 and hormonal agent QLs (inv-162)
    Sildenafil QL (10 EA per 30 days)Sildenafil citrate oral tablets are listed with QL 10 EA per 30 days (and ENH designation on some lines).
    Tadalafil (ED) QL (6 EA per 30 days)Tadalafil oral tablet (ED) is listed with QL 6 EA per 30 days and ENH on some lines.
    Estradiol patch QL (8 EA per 28 days)Estradiol transdermal patch twice-weekly shows QL 8 EA per 28 days; weekly patches show QL 4 EA per 28 days.
    Tadalafil quantity limit (inv-163)
    Tadalafil (ED) QL = 6 EA per 30 daysTadalafil oral tablet (ED) is listed with Requirements/Limits = ENH; QL (6 EA per 30 days) in the formulary table.
    ENH noteTadalafil entries show ENH (enhanced) designation indicating nonstandard Part D coverage treatment; pay attention to out-of-pocket and non-counting rules.
    TierTadalafil entries are listed at Tier = 2 where ENH/QL are shown.
    EOHILIA volume QL (inv-164)
    EOHILIA QL (600 ML per 30 days)EOHILIA oral suspension 2 mg/10 mL is listed with Requirements/Limits = PA; QL (600 mL per 30 days).
    PA requirementEOHILIA also carries a PA flag in the Requirements/Limits column in addition to the large-volume QL.
    TierEOHILIA is assigned Tier = 5 in the formulary where PA and QL are applied.
    Transdermal patch quantity limits (inv-165)
    Transdermal patches QL (8 EA per 28 days)Various transdermal patches (twice-weekly presentations) are listed with QL 8 EA per 28 days in the formulary table.
    Weekly patch QL (4 EA per 28 days)Some weekly transdermal patch presentations are listed with QL 4 EA per 28 days (e.g., weekly estradiol patches).
    EDS/PA interplayPatch entries may also include EDS or PA flags; confirm the specific Requirements/Limits cell for dispensing rules.

    Site-of-Care and Pharmacy Limitations

    Billing Rule

    ARIKAYCE: PA and limited access (may require specialty pharmacy)

    ARIKAYCE is marked 'PA; LA', indicating limited access and PA requirements that may restrict dispensing to specialized pharmacies or infusion/authorized providers; coordinate with the plan or specialty pharmacy for appropriate site‑of‑care dispensing.

    • LA indicates the drug may be available only at certain pharmacies — consult the Pharmacy Directory or Member Services
    Prior Authorization

    Diclofenac gel: specialist exemption for PA

    Diclofenac gel is listed with PA but the formulary specifically notes that prior authorization is not required for dermatologists or oncologists; when applicable, document the prescriber's specialty with the claim or PA request.

    Billing Rule

    Site‑of‑care and administration setting may affect PA and billing

    Some IV/infusion products and hospital/clinic‑administered therapies (for example CLINIMIX, PLENAMINE, PROLASTIN‑C) carry BD/PA/LA flags and tiering — site‑of‑care restrictions or billing designations may apply and prescribers should confirm appropriate administration setting and documentation.

    • BD indicates a potential Part B/Part D determination; consult plan guidance for site‑of‑care billing
    • PROLASTIN‑C and CLINIMIX show PA/LA/BD designations — coordinate with the plan for authorization and site‑of‑care

    Legend and Glossary

    Background / Scope

    The formulary is organized by medical condition and drug class; each drug line shows its formulary tier and may include utilization controls such as Prior Authorization (PA), Quantity Limits (QL), and Step Therapy (ST). Providers should follow the Requirements/Limits flags shown on each line when seeking coverage.